{
    "pmcid": "8061467",
    "qa_pairs": {
        "How do some nanobodies, like Ty1, demonstrate versatility in neutralizing SARS-CoV-2?": [
            "They bind to the RBD in both 'up' and 'down' conformations.",
            "They target multiple proteins on the virus surface simultaneously.",
            "They change their conformation to mimic the ACE2 receptor.",
            "They integrate into the viral genome to inhibit replication."
        ],
        "What is a key characteristic of nanobodies that makes them valuable for biomedical applications?": [
            "They are highly specific, stable, and soluble.",
            "They are glycosylated, which enhances their stability.",
            "They are larger than conventional antibodies, providing more binding sites.",
            "They require complex mammalian cell systems for production."
        ],
        "What is a potential challenge in the development of nanobodies for therapeutic use against SARS-CoV-2?": [
            "Their novel structural characteristics require rigorous quality, safety, and efficacy testing.",
            "Their large size makes them difficult to produce at scale.",
            "They are highly glycosylated, complicating their production.",
            "They have low specificity compared to conventional antibodies."
        ],
        "What is one advantage of producing nanobodies in microbial systems like bacteria or yeast?": [
            "It is cost-effective and allows for large-scale production.",
            "It enhances the glycosylation of nanobodies.",
            "It increases the size of nanobodies for better epitope coverage.",
            "It requires less rigorous quality control measures."
        ],
        "Which nanobody has shown increased neutralizing capacity when converted into a bivalent Fc fusion form?": [
            "VHH-72",
            "Ty1",
            "NIH-CoVnb-112",
            "VHH-82"
        ]
    }
}